Moderna News and Biotech Innovation Updates
Moderna Inc. (NASDAQ: MRNA) is a biotechnology company specializing in messenger RNA (mRNA) therapeutics and vaccines. Best known for its COVID-19 vaccine, Moderna leverages mRNA technology to develop treatments for infectious diseases, cancer, autoimmune conditions, and rare genetic disorders. Its modular platform enables rapid drug development and scalable manufacturing, positioning the company at the forefront of biotech innovation. Headquartered in Cambridge, Massachusetts, Moderna continues to expand its clinical pipeline and forge strategic partnerships with governments and research institutions worldwide. The company's long-term mission is to transform medicine by unlocking the potential of mRNA to treat and prevent a wide range of diseases.
231.35
17.3600
6.98 %
At close
11/12
USD
Daily range
229.69
245.37
245.37
Weekly range
229.69
280.75
280.75
Moderna shares fall nearly 7% as upbeat forecasts and cancer vaccine data fail to buoy stock
Moderna Inc (MRNA) fell 6.81% after delivering a batch of positive updates, including a raised 2026 revenue growth forecast and promising data for its cancer vaccine. The drop in price contradicts ...
Moderna outlined the next phase of growth after muted trading session
Moderna outlined plans for the next stage of its business at its 2026 Analyst Day. The stock edges lower on the day, trading at $248.69.Moderna outlined the next phase of growth at its 2026 ...
Moderna reported financial results and business updates: Will MRNA hold the MA-20?
Moderna reported financial results and provided an update on its business for the third quarter of 2026. The stock is down 6.4% on the day at $241.46.Moderna reported its financial results and ...
Why is Moderna stock down 6.6% today?
Moderna Inc. (MRNA) fell 6.68% after hitting a 52-week high, as investor reaction cooled despite recent advances in the company's vaccine and therapeutic development programs. The move shows ...
Moderna stock rises 8.8% after mRNA-1469 Phase 2/3 trial advance
Moderna announced that its investigational mRNA-1469 vaccine candidate for Bundibugyo ebolavirus is set to advance into a Phase 2/3 efficacy study in the Democratic Republic of the Congo, a step ...
MRNA climbs nearly 3% after strong Phase 3 cancer vaccine data and bullish technical signals
Moderna Inc. (MRNA) advanced 2.73% after positive Phase 3 data for its personalized mRNA cancer vaccine generated strong investor demand. The rally is supported by a bullish technical structure, ...
Moderna shares gain almost 4% after strong Phase 3 melanoma vaccine results and technical breakout
Moderna Inc (MRNA) advanced 3.98% after its recently reported Phase 3 trial results for the personalized melanoma vaccine combination with Keytruda continued to fuel buying interest. The move is ...
What's behind Moderna's latest 3.5% stock surge?
Moderna Inc. (MRNA) jumped 3.5% after detailed Phase 3 trial data for its personalized mRNA melanoma vaccine, intismeran, was presented, showing a significant reduction in disease recurrence when ...
Moderna announces detailed Phase 3 INTerpath-001 trial results as stock falls 1.4%
Moderna announced detailed results from the Phase 3 INTerpath-001 trial of its investigational individualized neoantigen therapy in partnership with Merck. The stock is down 1.4% on the day at ...
Moderna announces detailed positive Phase 3 study results: Can MRNA break above $198.48?
Moderna announced detailed positive results from a Phase 3 study of its investigational mRNA-based individualized neoantigen therapy, intismeran autogene, evaluated in combination with Merck's ...
MRNA jumps over 4% after renewed institutional interest and bullish momentum
Moderna Inc (MRNA) surged 4.13% after its upcoming inclusion in the Nasdaq-100 index on October 9, 2026, drew renewed institutional and passive fund interest to the stock. The move is strongly ...
What's behind Moderna's latest 9.8% stock pullback?
Moderna Inc (MRNA) slumped 9.78% after opening with a significant downside gap, as enthusiasm surrounding the upcoming October 24 release of late-stage trial data for its mRNA cancer vaccine ...
Moderna stock resistance test at $197.74: Key levels to watch
Moderna (MRNA) stock is trading at $187.91 after a marginal increase for the session. The price remains below its key short-term and medium-term moving averages, but ...
MRNA slides around 6.5% as volatility contrasts with strong momentum signals
Moderna Inc (MRNA) dropped 6.45% today after sharp downside pressure encountered by the stock, even as recent bullish catalysts included its addition to the Nasdaq-100 Index and optimism around ...
Why is Moderna stock down 6.6% today?
Moderna Inc (MRNA) slumped 6.62% after multiple analysts downgraded the stock to Sell, raising concerns that its valuation has outpaced fundamentals even as the company reported positive results ...
Moderna rally accelerates before ESMO as traders watch for signs of exhaustion
Investors are once again pricing greater confidence in Moderna’s cancer vaccine program into the stock. From here, fresh developments could either extend the rally or give traders a reason to ...
What's behind Moderna's latest 8.0% stock surge?
Moderna Inc (MRNA) surged 8.02% after the FDA approved its XFG-adapted Spikevax and mNexspike COVID-19 vaccine formulas for the 2026-2027 season and positive Phase 3 results for its melanoma ...
Moderna remains overheated despite pullback as downside risk stays elevated
Moderna remains one of the most overheated biotech stocks after its powerful summer rally. The correction has already removed part of the extreme momentum, but the coming weeks could bring ...
Moderna stock price prediction: Range-bound trading expected
Moderna (MRNA) stock is trading at $145.55, down 2.23% for the session and hovering near the day’s low on elevated volatility. The price remains beneath its key ...
Moderna breaks higher as healthcare becomes market’s safe haven
Moderna stock partially played out the previous scenario, falling to $133.33 and stopping just short of the $131 target. A sharp reversal then followed, with MRNA recovering more than 15% from ...
MRNA climbs nearly 6% after upbeat Phase 3 melanoma vaccine results and strong technical momentum
Moderna Inc (MRNA) jumped 5.61% after its personalized mRNA melanoma vaccine, developed alongside Merck, achieved a positive Phase 3 clinical trial outcome. The rally is supported by a strong ...
